Acambis narrows first-half 2008 loss 37%
UK vaccines developer Acambis' interim pretax loss in the first six months of 2008 narrowed 36.8% to L12.2 million ($23.9 million), as revenues more than doubled to L8.8 million from L3.4 million.
The firm's results were boosted by a milestone from vaccines giant Sanofi Pasteur, the vaccines division of French drug major Sanofi-Aventis, when it extended their ChimeriVax-JE vaccine license to include India and the Indian subcontinent (Marketletter April 7).
Acambis granted Sanofi marketing, distribution and certain manufacturing rights to its single-dose Japanese encephalitis vaccine in February 2007. The company's board of directors has also recommended acceptance of the Sanofi's L276.0 million buy out offer (Marketletter August 4).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze